News
NICE recommends new CAR-T treatment for lymphoma for some patients on NHS
BMJ 2021; 372 doi: https://doi.org/10.1136/bmj.n184 (Published 20 January 2021) Cite this as: BMJ 2021;372:n184
- Elisabeth Mahase
- The BMJ
Some patients with relapsed or refractory mantle cell lymphoma will now be able to access a new CAR-T treatment, which uses their own re-engineered white blood cells to attack cancer cells, through the NHS.1
The new treatment has been made available after recommendation from the National Institute for Health and Care Excellence (NICE). The guidance, issued on 19 January, says that Tecartus (also known as autologous anti-CD19-transduced CD3+) can be …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £157 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£30 / $37 / €33 (excludes VAT)
You can download a PDF version for your personal record.